Red
Brand Name(s):Iressa
Indication:First-line treatment of locally advanced or metastatic non-small cell lung cancer
Rationale:1,2,8
Considered:May-09
Review Date:Sep-20
Comments:
Gefitinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:
* they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and
* the manufacturer provides gefitinib at the fixed price agreed under the patient access scheme.
NICA TA 192
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer July 2010